The True FCF yield on the S&P 500 is running 2.51% below the 10-year treasury. That negative risk premium has shown up a few times since 1987, and it doesn't portend good things...

Two separate things are happening in the market simultaneously and most analysis treats them as separately. The Macro angle: Warsh is keeping rates flat while NGDP runs hot. Longer rates are already backing up, and that sequence historically ends one of four ways and none of them are comfortable for today's equity multiples. The Valuation angle: the S&P 500 earnings yield is 3.48% against a 4.59% 10-year treasury, negative by 1.11%. But that earnings yield has been inflated by companies reporting GAAP income while piling CapEx and SBC into the denominator. Once you use True FCF yield instead of earnings yield, the gap opens to negative 2.51%. That -2.51% figure is not unprecedented. It shows up in the scatter plot in 1987, 1992, 2000, and in the 2008 aftermath when earnings collapsed. In every case something big happened to resolve the gap, either earnings rose dramatically or prices fell. The chart that makes this concrete: there's a stability band between 5-7% treasury yields where equity risk premiums get thin and multiples get rich because monetary policy is calm. Below 4% you get post-crisis fear and big equity risk premiums. Above 8% you get inflation fear and big equity risk premiums. The 5-7% band is where nobody is scared and "everything is awesome". We're at 4.6-4.7%. Just below the lower edge of the stability band. Close enough that today's thin risk premiums are defensible historically, but not so close that I'm comfortable buying the index. How I'm positioned to survive the four scenarios I think are plausible: * USFR 18.79%: explicit optionality for tail scenarios. Converts to equity in one trade. * CMCSA 14.28%: 17.5% True FCF yield on a spinoff that closes the conglomerate discount regardless of what Warsh does. * CB 9.40%: insurance float compounder that owns short-duration bonds. Goes up in the scenarios where everything else goes down. * ADBE 9.39%: beaten-down SaaS dying of a theory. Cash flows still marching on. * BRK.B 9.30%: $334B in cash waiting for the moment the risk premium gap resolves. * THC 8.72%: USPI ambulatory surgery platform trading at 40% discount to standalone value. Healthcare demand doesn't depend on Warsh getting it right. * EPD 8.51%: PPI-indexed midstream infrastructure with fixed long-dated debt. Cleanest inflation hedge in the portfolio. * FRFHF 7.08%: Fairfax Financial, float compounder with opportunistic capital allocation on top. Trading at 1.3x book while growing book value 20%+ annually. I had HCI as a starter position but liked FRFHF's valuation more. HCI is still on my watch list. * FDS 6.71%: four consecutive quarters of ASV acceleration while being sold as an AI casualty. * EOG 4.45%: direct Hormuz risk premium bet, sized small because slowing economy cuts demand at the same time supply shock pushes price up. * CF 3.34%: nitrogen producer, newest and smallest position, sized like I'm not totally sure yet. Weighted average True FCF yield: 8%. Risk premium over the 4.6% 10-year: plus 3.4%. Full piece with scatter plots, the True FCF divergence chart, and the complete allocation table: [https://cavemanscreener.substack.com/p/macro-vs-free-cash-flow-yield-a-thesis](https://cavemanscreener.substack.com/p/macro-vs-free-cash-flow-yield-a-thesis)